- Provides the most up to date information regarding conventional forms of cytotoxic chemotherapy, as well as the basic science and clinical application of molecular therapeutics, for the treatment of brain tumors
- Broadly appeals to anyone interested in the field of Neuro-Oncology and in the treatment of patients with brain tumors
- Useful to clinicians interested in a thorough overview of the use of chemotherapy in patients with a broad range of brain tumors as well as serving as a source of background information to basic scientists and pharmaceutical researchers with an interest in the molecular therapeutics of brain tumors
The book provides a broad overview of the current "state-of-the-art" in the use of chemotherapy for primary and metastatic brain tumors and includes information on traditional (e.g., alkylating agents, spindle poisons, topoisomerase inhibitors, etc) and non-traditional (e.g., intra-arterial approaches, blood-brain barrier disruption, etc) forms of chemotherapy. In addition, newer molecular-based chemotherapeutic agents (e.g., tyrosine kinase inhibitors, ras pathway inhibitors, PI3 kinase inhibitors, mTOR inhibitors, angiogenesis inhibitors, etc) are included. Well-founded in basic science and pharmacology, the chapters provide an overview of relevant background material in critical areas such as drug pharmacology and mechanisms of action, molecular biology (e.g., critical oncogenes, tumor suppressor genes), signal transduction pathways, angiogenesis pathways, and developmental pharmacology.